NeuroMind BioPharma

Videos

Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing

The company is currently listed on Canada’s NEO exchange and has a market cap of $190 million. MindMed’s announcement comes just days after U.K.-based Compass Pathways, which has patented a synthetic form of psilocybin for use in treatment-resistant depression, went public on the Nasdaq. Compass’ IPO is perhaps a bellwether signaling that some Wall Street […]

Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing Read More »

NeuroMind BioPharma Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (“MindMed” or the “Company”) is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately. Dr. Vinson is a Triple Board-Certified physician who specializes in adult, child & adolescent,

NeuroMind BioPharma Announces Appointment of Dr. Sarah Y. Vinson as Additional Director Read More »